NCT03740555 - A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

July 19, 2019

Study Completion Date

July 19, 2019

Conditions

Healthy

Interventions

DRUG

HNC042 single dose

HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg

DRUG

Placebo single dose

Placebo single ascending doses , Intravenous route Single dose, matching placebo

DRUG

HNC042 multiple ascending doses

HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg

DRUG

Placebo multiple ascending doses

Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo

Trial Locations (1)

Paolo B. DePetrillo, Baltimore

All Listed Sponsors

lead

Guangzhou Henovcom Bioscience Co. Ltd.

INDUSTRY